AbbVie's Allergan division secured European regulatory approval for Boey, a rapid-onset botulinum toxin formulation designed to deliver results faster than standard neuromodulators. The product addresses a long-standing patient pain point: the 7–14 day wait for full effect with traditional toxin, which can deter first-time and event-driven patients.
Injectables
AbbVie Wins EU Approval for Boey — What Rapid-Onset Botox Means for Your Toxin Mix
Allergan's new neuromodulator shows faster onset than traditional botulinum toxin; U.S. launch timing unclear.
1-YEAR MOVE
ABBV▲11.6%
| Ticker | Company | 1-year change |
|---|---|---|
| ABBV | AbbVie (Allergan Aesthetics) | +11.6% |
Rapid-onset formulation targets the 7–14 day wait that deters first-time and event-driven patients.
Boey's mechanism leverages a proprietary formulation to accelerate diffusion and receptor binding. For practices, the clinical edge is real—faster onset can reduce cancellations and improve patient satisfaction scores. However, U.S. FDA approval remains pending, and pricing relative to Botox, Dysport, and Jeuveau is unknown. Practices should monitor the 510(k) or PMA pathway and watch for launch timing and rebate programs through Alle or Aspire.
Source: original report ↗
Free alerts
Free: recall & rule-change alerts for your practice.
Get the recalls and state-law changes that hit your treatment room, in your inbox — free. Unsubscribe in one click.
Free · weekly · unsubscribe anytime. Privacy.
Stay three moves ahead of every practice in your market.
Knowing it happened is table stakes. Inside MedSpa Pro hands you the play — what each move means for your margins, your license, and your patients, and exactly what to do about it — in a two-minute brief, twice a week. The owners who read it never get blindsided.
Get the edge · $20/moJoin the owners who run ahead of the industry. Cancel anytime, one click.